Citations

Clear

5 citation(s) found for "Ahmed, Adnan".

Abstract 4146453: Efficacy of Bilateral Cardiac Sympathetic Denervation in Treating Different Etiologies of Nonischemic Cardiomyopathy: A Subset Analysis
Darden, Douglas , Pothineni, Naga Venkata K. , Kabra, Rajesh , Romeya, Ahmed, Atkins, Donita, Lakkireddy, Dhanunjaya , Ghazal, Rachad , Chelikam, Nikhila , Katapadi, Aashish , Ahmed, Adnan , Bawa, Danish , Gopinathannair, Rakesh

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4146453 Get It

Background: Bilateral cardiac sympathetic denervation (BCSD) has shown promise in treating patients with nonischemic cardiomyopathy (NICM) suffering from refractory multifocal premature ventricular contractions (PVCs) and ventricular tachycardia (VT). Despite its growing use, the effectiveness of BCSD across different NICM etiologies has not been extensively studied. Research Question: How effective is BCSD across a variety of NICM etiologies? Goals: To evaluate the effectiveness of BCSD on left ventricular ejection fraction (LVEF) and PVC burden in patients with NICM. Methods: We conducted a subset analysis on a previous retrospective, observational study of NICM patients who underwent BCSD. Eight NICM etiologies were assessed. Results: 43 NICM patients underwent BCSD (mean age 52.3±14.7 years; 30% females). Overall, LVEF significantly improved (38.7±7.9% to 46.2±9.6%, p <0.001), and PVC burden (PVCb) significantly decreased (23.7±9.9% to 1.3±1%, p <0.001). A similar phenomenon was seen in idiopathic/dilated cardiomyopathy (CM) (LVEF: +8.7%, p <0.001; PVCb: -20.6%, p <0.001), post-viral CM (LVEF: +4.8%, p =0.2; PVCb: -24.2%, p <0.001), familial CM (LVEF: +10%; PVCb: +23.3%), giant cell CM (LVEF: +10%; PVCb: + 30.5%), and arrhythmogenic right ventricular CM (LVEF: +12.5%, p=0.09; PVCb -30.6%, p =0.001). Catecholaminergic polymorphic VT had a non-significant increase in LVEF (+5%, p=0.5) but a significant decrease in PVCb (-21.8%, p=0.02), whereas sarcoidosis had the opposite effect with significant increase in LVEF (LVEF: +13.4%, p=0.3) but non-significant decrease in PVCb (-16.1%, p=0.02). Lastly, hypertrophic CM remained unchanged in LVEF (30%) but PVCb decreased (-8%). Conclusion: BCSD demonstrates efficacy in improving LVEF and reducing PVCb across almost all NICM with refractory VT. However, a case-by-case evaluation is still needed for its use.
Abstract 13351: Impact of a Second Incident Arrhythmia on Outcomes in Hospitalized COVID-19 Patients: Insights From the COVID-RHYTHM Registry
Ahmed, Adnan , Charate, Rishi , Trivedi, Jaimin R. , Kabra, Rajesh , Stavrakis, Stavros , Aksu, Tolga , Saha, Sandeep , Liu, Zhenguo , Padmanabhan, Deepak , Al‐Ahmad, Amin , Lakkireddy, Dhanunjaya, Bawa, Danish , Russo, Andrea M, Wan, Elaine Y. , Mar, Philip L. , Gautam, Sandeep , Dominic, Paari , Asad, Zain Ul Abideen , Shenthar, Jayaprakash , Natale, Andrea , Lakkireddy, Dhanunjaya, Gopinathannair, Rakesh

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.13351 Get It

Introduction: Incident cardiac arrhythmias are common in hospitalized COVID-19 patients, but the impact of a second incident cardiac arrhythmia during hospitalization on clinical outcomes remain unclear. Hypothesis: The aim of this study was to assess the frequency and prognostic implications of a second incident arrhythmia in hospitalized COVID-19 patients over the pandemic course till vaccine availability. Methods: The multicenter COVID-RHYTHM Registry enrolled hospitalized COVID-19 patients from 3/8/2020 to 1/24/2021. Cardiac arrhythmia included documented atrial fibrillation (AF), atrial flutter (AFL), ventricular tachycardia (VT), severe sinus bradycardia (<40 bpm) or AV block. Outcomes were compared between patients with single vs. more than one incident arrhythmias adjusting for baseline variables. Results: Of 6299 hospitalized COVID-19 patients, 4398 had an had an incident cardiac arrhythmia during hospitalization, of which 822 (19%) had a second incident arrhythmia. Those with >1 incident arrhythmia had a higher baseline prevalence of heart failure, chronic kidney disease, coronary artery disease and sleep apnea (Table). Those with >1 incident arrhythmia had higher in-hospital mortality, need for ICU admission and need for rehab upon discharge. Length of stay was similar between the groups. Conclusions: In hospitalized COVID-19 patients with incident cardiac arrhythmias, a second incident arrhythmia during hospitalization was seen in 19%. Having >1 incident arrhythmia was associated with increased need for ICU admission and reduced survival.
Abstract 15045: Impact of Left Ventricular Assist Device (LVAD) Type on Arrhythmic Outcomes in Patients With Continuous Flow LVADs
Lakkireddy, Dhanunjaya , Pothineni, Naga Venkata K. , Roukoz, Henri , Bhan, Adarsh , Ahmed, Mustafa M. , Ahmed, Adnan , Charate, Rishi , Atkins, Donita, Padmanabhan, Deepak , Trivedi, Jaimin R. , Gopinathannair, Rakesh , Gautam, Sandeep , Mar, Philip L. , Slaughter, Mark S.

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.15045 Get It

Introduction: Cardiac arrhythmias are common in continuous flow left ventricular assist device (LVAD) recipients. The impact of axial vs. intrapericardial centrifugal LVAD pumps on arrhythmia incidence and associated clinical outcomes is unclear. Hypothesis: This multicenter study evaluated the impact of LVAD type (axial vs. centrifugal) on incidence of atrial and ventricular arrhythmias, ICD shocks and mortality in LVAD patients. Methods: Analysis was done on 536 patients who underwent LVAD implantation at 5 US centers from 2008 to 2016. The groups were divided based on their LVAD type (axial - HeartMate II [HMII, n=433] vs. centrifugal - HeartWare (HW, n=103). Baseline characteristics as well as incidence of post-LVAD atrial arrhythmias (PL-AA), ventricular arrhythmias (PL-VA) and ICD shocks were analyzed in these groups. Multivariable Cox Regression analysis was used to identify predictors of survival. Results: Of 536 patients, 433 had HMII axial LVAD and 103 had HW centrifugal VAD implant. At baseline, HMII group had more males, higher proportion of CRT-D and higher prevalence of AA (Table 1A). Left ventricular dimensions were similar between groups. During a median follow-up of 537 days of LVAD support, incidence of PL-VA and ICD shocks were significantly higher in the HM2 group compared to HW group whereas incidence of PL-AA was not significantly different (Table 1A). In multivariable Cox Regression analysis, LVAD indication was the only variable that predicted survival (Table 1B). Type of LVAD (axial vs. centrifugal) was not associated with survival (HMII vs. HW - HR 1.04, P=0.48). Conclusions: In this multi-center continuous flow LVAD cohort, axial HM2 VAD patients had a higher incidence of PL-VA and ICD shocks. Type of LVAD (axial vs. centrifugal) was not associated with survival.
Abstract 10228: Efficacy and Safety of Catheter Ablation in Patients with Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
Junarta, Joey , Ahmed, Adnan , Pasha, Ahmed K. , Alvarez, René , Siddiqui, Muhammad Umer , Frisch, Daniel R.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10228 Get It

Background: Catheter ablation for atrial fibrillation is a proven alternative to pharmacologic rhythm control in patients with heart failure with reduced ejection fraction (HFrEF). Whether outcomes differ in patients with heart failure with preserved ejection fraction (HFpEF) is of interest. Methods: Medline, Scopus, and Cochrane Central Register of Controlled Trials were systematically searched to identify relevant studies. We extracted or calculated a risk ratio (RR) and 95% confidence intervals (CI) from each study. Primary outcomes of interest include atrial arrythmia recurrence and repeat ablation. Harm outcomes of interest include all-cause mortality, all-cause hospitalizations, cardiovascular hospitalizations, stroke/transient ischemic attack, and cardiac tamponade. Results: We included 7 observational studies comprising 2,525 patients with HFpEF who underwent catheter ablation for atrial fibrillation. There were no significant differences in primary and harm outcomes when comparing catheter ablation for atrial fibrillation in patients with HFpEF to patients with no heart failure. Similarly, there were no significant differences in outcomes when comparing catheter ablation for patients with HFpEF to HFrEF. The certainty in these estimates was low. Conclusions: Non-randomized studies suggest that catheter ablation for atrial fibrillation in patients with HFpEF is associated with similar arrythmia free survival and safety profile when compared to patients with HFrEF and without heart failure. This suggests that patients with AF and HFpEF may benefit equally from catheter ablation as those with AF and HFrEF.
Adjuvant steroid therapy in community‐acquired pneumonia: A systematic review and meta‐analysis
Shafiq, Mājid , Mansoor, Muhammad Sohail , Sohail, M. Rizwan , Murad, M. Hassan , Khan, Adnan Ahmed , Murad, M Hassan , Sohail, M Rizwan

Mayo Clinic

Journal of Hospital Medicine | November 26, 2012 | Volume: 8 | Issue: 2 | Pages: 68-75

10.1002/jhm.1992 | PMID 23184813 Get It

BACKGROUNDCommunity‐acquired pneumonia (CAP) is a leading cause of morbidity and mortality among adults. Although steroids appear to be beneficial in animal models of CAP, clinical trial data in humans are either equivocal or conflicting.PURPOSEOur purpose was to perform a systematic review and meta‐analysis of studies examining the impact of steroid therapy on clinical outcomes among adults admitted with CAP.DATA SOURCES AND STUDY SELECTIONWe identified randomized controlled trials (RCTs) through a systematic search of published literature up to July 2011.DATA EXTRACTIONWe estimated relative risks (RR) and weighted mean differences, pooled from each study using a random effects model.DATA SYNTHESISEight RCTs, comprising 1119 patients, met our selection criteria. Overall quality of the studies was moderate. Adjunctive steroid therapy had no effect on hospital mortality or length of stay in the intensive care unit, but reduced the overall length of hospital stay (RR: −1.21 days [95% confidence interval (CI): −2.12 to −0.29]). Less robust data also demonstrated reduced incidence of delayed shock (RR: 0.12 [95% CI: 0.03 to 0.41]) and reduced persistence of chest x‐ray abnormalities (RR: 0.13 [95% CI: 0.06 to 0.27]). A priori subgroup and sensitivity analyses did not alter these findings.CONCLUSIONSModerate‐quality evidence suggests that adjunctive steroid therapy for adults hospitalized with CAP reduced the length of hospital stay but did not alter mortality. Journal of Hospital Medicine 2013;8:68–75. © 2012 Society of Hospital Medicine